Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 112Breast Neoplasms 17Neoplasms 7Leiomyoma 6Prostate Adenocarcinoma 3Polycystic Ovary Syndrome 3Salivary Gland Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Uveal Melanoma 1Stage I Prostate Adenocarcinoma AJCC v7 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasm Duct 1Recurrence 1Puberty, Precocious 1Primary Dysautonomias 1Premenopausal Breast Cancer 1Patient Compliance 1PSA Level Greater Than Two 1Obesity, Morbid 1Obesity 1Myofibroma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Melanoma 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Sensitive Prostate Cancer × Leuprolide × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡